Horizon Pharma Names Brian K. Beeler Executive Vice President And General Counsel

DUBLIN, IRELAND--(Marketwired - May 08, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Brian K. Beeler as general counsel, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Beeler has also joined the Company’s Executive Committee.

“Since Brian joined Horizon Pharma, he has been instrumental in guiding our legal and compliance functions, which are vital to our long-term success,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “I have absolute confidence that as general counsel, Brian will continue to provide exemplary guidance and to help us navigate our growing business.”

Beeler joined Horizon Pharma in 2013 as associate general counsel and chief compliance officer and was promoted to senior vice president, legal and chief compliance officer in January 2015. He has more than 15 years of experience providing counsel to businesses in the healthcare and life sciences industries. During his time at Horizon Pharma, Beeler played key roles in leading all compliance activities and facilitating mergers and acquisitions, including the acquisition of Vidara Therapeutics International plc in September 2014 and the acquisition of Hyperion Therapeutics this month.

“I am honored to be named general counsel and to be part of a growing, evolving company that embodies a true ‘patients first’ mentality in every aspect of the business,” said Beeler.

Prior to joining Horizon Pharma, Beeler served as associate general counsel for Fenwal, Inc., a global life sciences manufacturer of products for transfusion medicine. Prior to Fenwal, he was senior counsel, Business Development, Commercial and Research and Development at TAP Pharmaceuticals and Takeda Pharmaceuticals North America. Beeler also previously served as chief compliance officer at Schwarz Pharma.

Beeler is licensed to practice law in the states of Illinois and Indiana. He received his JD from Indiana University School of Law, his MBA from Kellogg School of Management at Northwestern University and his BA from Purdue University.

In addition, the Company named Tim Ayers vice president and chief compliance officer. Ayers has extensive experience in the biopharmaceutical industry, having served most recently as a principal and vice president at the legal practice of Porzio, Bromberg & Newman in the Life Sciences Compliance, Commercialization and Regulatory Counseling Department. Prior, he served as vice president and chief compliance officer at Dendreon Corporation, where he was responsible for the development and implementation of a company-wide compliance program in the United States and European Union.

Ayers received his bachelor’s degree and JD from Georgetown University and his master’s in public health from Columbia University.

About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon’s global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.